QQQ   563.81   (+0.46%)
Why Meta’s AI Titan Clusters Are a Game-Changer for Broadcom
5 Stocks to Buy and Hold for the Rise of Physical AI
2 Chinese Stocks That Could Leave U.S. Tech in the Dust
4 Major Stocks Raise 2025 Guidance, Analyst Targets Rise
The Bottom Is in for Kohl’s, But Let the Share Price Come to You
What's Behind Opendoor Technologies' Rally? Is Meme Mania Back?
Healthcare Stocks Hit Valuation Bottom, 3 Names to Rebound
QQQ   563.81   (+0.46%)
Why Meta’s AI Titan Clusters Are a Game-Changer for Broadcom
5 Stocks to Buy and Hold for the Rise of Physical AI
2 Chinese Stocks That Could Leave U.S. Tech in the Dust
4 Major Stocks Raise 2025 Guidance, Analyst Targets Rise
The Bottom Is in for Kohl’s, But Let the Share Price Come to You
What's Behind Opendoor Technologies' Rally? Is Meme Mania Back?
Healthcare Stocks Hit Valuation Bottom, 3 Names to Rebound
Free Trial
NASDAQ:INAB

IN8bio Q2 2024 Earnings Report

IN8bio logo
$2.46 +0.09 (+3.80%)
Closing price 04:00 PM Eastern
Extended Trading
$2.48 +0.02 (+1.02%)
As of 07:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

IN8bio EPS Results

Actual EPS
-$5.70
Consensus EPS
-$4.80
Beat/Miss
Missed by -$0.90
One Year Ago EPS
N/A

IN8bio Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

IN8bio Announcement Details

Quarter
Q2 2024
Time
After Market Closes
Conference Call Date
Thursday, August 8, 2024
Conference Call Time
4:00PM ET

Upcoming Earnings

IN8bio's Q2 2025 earnings is scheduled for Thursday, August 14, 2025, with a conference call scheduled on Friday, August 8, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

IN8bio Earnings Headlines

Google did what!?!?
A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bill Gates has backed four companies in this space. The World Economic Forum calls it “the most exciting human discovery since fire.” Whitney Tilson believes this trend could mint a new class of wealthy investors—and he’s sharing one stock to watch now, for free.
See More IN8bio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like IN8bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on IN8bio and other key companies, straight to your email.

About IN8bio

IN8bio (NASDAQ:INAB), a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidates include INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation; and INB-400, which is in Phase 2 clinical trial to treat newly diagnosed GBM. It also develops INB-300, INB-410, and INB-500 that are in preclinical Phase for treatment of various solid tumor cancers. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York.

View IN8bio Profile

More Earnings Resources from MarketBeat